Fluorouracil: Clinical Trials

1,990 trials of Fluorouracil, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

949 completed, 312 unknown, 241 recruiting, 205 terminated. 1109 Phase 2, 543 Phase 3, 400 Phase 1, 66 Not applicable, 44 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21109Completed 504, Unknown 171, Terminated 140, Recruiting 128, Active not recruiting 67, Withdrawn 57, Not yet recruiting 38, Suspended 3, Enrolling by invitation 1
Phase 3543Completed 268, Unknown 98, Recruiting 64, Active not recruiting 37, Terminated 36, Not yet recruiting 24, Withdrawn 14, Suspended 2
Phase 1400Completed 202, Recruiting 64, Terminated 46, Active not recruiting 25, Unknown 25, Withdrawn 24, Not yet recruiting 13, Suspended 1
Not applicable66Completed 22, Unknown 19, Recruiting 10, Not yet recruiting 5, Terminated 5, Withdrawn 3, Active not recruiting 1, Enrolling by invitation 1
Phase 444Completed 17, Unknown 12, Not yet recruiting 6, Recruiting 3, Terminated 2, Withdrawn 2, Enrolling by invitation 1, Suspended 1
Early Phase 119Completed 10, Terminated 4, Active not recruiting 2, Recruiting 2, Unknown 1

Follow Fluorouracil: new trials by email Literature Review of Fluorouracil trials Research Report on Fluorouracil

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 3Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.8202027-06-302026-09-29
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Phase 2Not yet recruitingAbramson Cancer Center at Penn Medicine342027-04-012026-11-04
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.6002027-02-012026-09-14
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma
Phase 3RecruitingCity of Hope Medical Center1292027-01-042026-11-05
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer
Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer
Phase 2Not yet recruitingWashington University School of Medicine252026-12-312026-11-05
Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma
Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma
Phase 1 / Phase 2Not yet recruitingChildren's Oncology Group702026-12-112026-09-30
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Phase 1Not yet recruitingCity of Hope Medical Center302026-12-012026-09-02
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer
Phase 1 / Phase 2Not yet recruitingCytomX Therapeutics3682026-12-012026-10-28
QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients
Intervention 1 - Drug QL1706 (Iparomlimab and Tuvonralimab) Intervention 2 - Drug Lenvatinib Intervention 3 - Drug FOLFOX Chemotherapy (Oxaliplatin, Fluorouracil, and Levoleucovorin Calcium) - Hepatocellular Carcinoma (HCC)
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University332026-12-012026-11-12
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Phase 4Not yet recruitingAstellas Pharma Global Development, Inc.502026-11-302026-09-21
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma
Phase 3Not yet recruitingZhai Wenlong902026-11-302026-11-04
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
Irinotecan, Oxaliplatin, GFH276 - CRC
Phase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.1502026-11-152026-11-06
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms
Phase 4Not yet recruitingMerck Sharp & Dohme LLC1502026-11-062026-09-03
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
Not applicableRecruitingIMGT Co., Ltd.3662026-11-042026-11-09
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC)
Phase 2Not yet recruitingSun Yat-sen University2292026-11-012026-10-16
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Phase 2RecruitingNorthwestern University1252026-10-262026-10-29
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer
Phase 3RecruitingMerck Sharp & Dohme LLC4002026-10-232026-11-16
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Esophageal Adenocarcinoma
Phase 2RecruitingDuke University602026-10-212026-11-04
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors
Phase 2RecruitingMerck Sharp & Dohme LLC4802026-10-212026-11-16
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium) - Colorectal Neoplasms
Phase 1 / Phase 2Not yet recruitingShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.642026-10-202026-09-28

Showing 20 of 1990. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (503)  ·  Rectal Neoplasms (268)  ·  Colonic Neoplasms (220)  ·  Pancreatic Neoplasms (191)  ·  Stomach Neoplasms (190)  ·  Esophageal Neoplasms (135)  ·  Breast Neoplasms (120)  ·  Neoplasm Metastasis (118)  ·  Squamous Cell Carcinoma of Head and Neck (97)  ·  Neoplasms (94)  ·  Head and Neck Neoplasms (92)  ·  Adenocarcinoma Of Esophagus (73)  ·  Esophageal Squamous Cell Carcinoma (65)  ·  Carcinoma, Hepatocellular (57)  ·  Adenocarcinoma (43)

Sponsors

National Cancer Institute (NCI) (82)  ·  Sun Yat-sen University (61)  ·  M.D. Anderson Cancer Center (39)  ·  Fudan University (35)  ·  Alliance for Clinical Trials in Oncology (32)  ·  European Organisation for Research and Treatment of Cancer - EORTC (31)  ·  Memorial Sloan Kettering Cancer Center (31)  ·  UNICANCER (31)  ·  Hoffmann-La Roche (30)  ·  Merck Sharp & Dohme LLC (29)  ·  Sanofi (29)  ·  AstraZeneca (22)  ·  GERCOR - Multidisciplinary Oncology Cooperative Group (22)  ·  ImmunityBio, Inc. (21)  ·  Eli Lilly and Company (19)

Countries

United States (895)  ·  China (392)  ·  France (243)  ·  Germany (199)  ·  Italy (189)  ·  Spain (175)  ·  United Kingdom (165)  ·  Canada (159)  ·  Japan (134)  ·  South Korea (134)  ·  Belgium (118)  ·  Taiwan (110)  ·  Australia (109)  ·  Poland (81)  ·  Brazil (71)

Top investigators

Norman Wolmark, MD (9)  ·  David J. Adelstein, MD (6)  ·  Al B. Benson, MD, FACP (5)  ·  Alfredo Falcone, MD (5)  ·  Howard S. Hochster, MD (5)

Results publications

PMID 36306483, PMID 31268130, PMID 32816630, PMID 40341124, PMID 21997132, PMID 33356421, PMID 40207789, PMID 33439695, PMID 34037241, PMID 35623069, PMID 37139963, PMID 41252656, PMID 12049862, PMID 12540794, PMID 17960012, PMID 20797891, PMID 21561347, PMID 23265711, PMID 23493136, PMID 24982463, PMID 26187751, PMID 26861604, PMID 27275632, PMID 27722750, PMID 27986363, PMID 28006055, PMID 28237539, PMID 28797458, PMID 29471013, PMID 30293873, PMID 30679026, PMID 31070690, PMID 31378656, PMID 31811950, PMID 32085892, PMID 32418078, PMID 32939319, PMID 33538338, PMID 33684371, PMID 33792646, PMID 34795131, PMID 34905388, PMID 35594613, PMID 36525610, PMID 36572280, PMID 36940261, PMID 37037952, PMID 37699333, PMID 37957132, PMID 38315963

NIH funding

2023 (22), 2017 (19), U10CA032102 (18), 2016 (17), 2018 (15), 2014 (14), 2015 (13), 2025 (13), U10CA031946 (13), U10CA180820 (13), 2019 (10), U10CA021115 (10), P30CA033572 (9), U10CA180868 (9), 2008 (8)